Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies

Amy C. Cannella; James Robert O'Dell

doi:10.1016/B978-0-323-93540-1.00061-0

Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

This chapter reviews the mechanism of action, pharmacology, indications, toxicity, and monitoring for the traditional disease-modifying drugs methotrexate, leflunomide, sulfasalazine, and hydroxychloroquine. The use of these medications in special populations, such as pediatric, geriatric, and pregnant patients, is discussed. Combination therapy with the traditional DMARDs is also reviewed.

Original language	English (US)
Title of host publication	Firestein & Kelley's Textbook of Rheumatology, 2-Volume Set
Publisher	Elsevier
Pages	1001-1024.e8
Volume	2
ISBN (Electronic)	9780323935401
ISBN (Print)	9780323935906
DOIs	https://doi.org/10.1016/B978-0-323-93540-1.00061-0
State	Published - Jan 1 2024

Keywords

combination DMARD therapy
disease-modifying anti-rheumatic drugs (DMARDs)
hydroxychloroquine
leflunomide
methotrexate
sulfasalazine

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/B978-0-323-93540-1.00061-0

Cite this

@inbook{d0460b5b5f94464dbf7d18d7fedae8f0,

title = "Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies",

abstract = "This chapter reviews the mechanism of action, pharmacology, indications, toxicity, and monitoring for the traditional disease-modifying drugs methotrexate, leflunomide, sulfasalazine, and hydroxychloroquine. The use of these medications in special populations, such as pediatric, geriatric, and pregnant patients, is discussed. Combination therapy with the traditional DMARDs is also reviewed.",

keywords = "combination DMARD therapy, disease-modifying anti-rheumatic drugs (DMARDs), hydroxychloroquine, leflunomide, methotrexate, sulfasalazine",

author = "Cannella, {Amy C.} and O'Dell, {James Robert}",

year = "2024",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-93540-1.00061-0",

language = "English (US)",

isbn = "9780323935906",

volume = "2",

pages = "1001--1024.e8",

booktitle = "Firestein & Kelley's Textbook of Rheumatology, 2-Volume Set",

publisher = "Elsevier",

}

TY - CHAP

T1 - Traditional DMARDs

T2 - Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies

AU - Cannella, Amy C.

AU - O'Dell, James Robert

PY - 2024/1/1

Y1 - 2024/1/1

N2 - This chapter reviews the mechanism of action, pharmacology, indications, toxicity, and monitoring for the traditional disease-modifying drugs methotrexate, leflunomide, sulfasalazine, and hydroxychloroquine. The use of these medications in special populations, such as pediatric, geriatric, and pregnant patients, is discussed. Combination therapy with the traditional DMARDs is also reviewed.

AB - This chapter reviews the mechanism of action, pharmacology, indications, toxicity, and monitoring for the traditional disease-modifying drugs methotrexate, leflunomide, sulfasalazine, and hydroxychloroquine. The use of these medications in special populations, such as pediatric, geriatric, and pregnant patients, is discussed. Combination therapy with the traditional DMARDs is also reviewed.

KW - combination DMARD therapy

KW - disease-modifying anti-rheumatic drugs (DMARDs)

KW - hydroxychloroquine

KW - leflunomide

KW - methotrexate

KW - sulfasalazine

UR - http://www.scopus.com/inward/record.url?scp=85217292514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85217292514&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-93540-1.00061-0

DO - 10.1016/B978-0-323-93540-1.00061-0

M3 - Chapter

AN - SCOPUS:85217292514

SN - 9780323935906

VL - 2

SP - 1001-1024.e8

BT - Firestein & Kelley's Textbook of Rheumatology, 2-Volume Set

PB - Elsevier

ER -

Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this